TY - JOUR
T1 - N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer
AU - Seko, Akira
AU - Kataoka, Fumio
AU - Aoki, Daisuke
AU - Sakamoto, Masaru
AU - Nakamura, Toshiaki
AU - Hatae, Masayuki
AU - Yonezawa, Suguru
AU - Yamashita, Katsuko
N1 - Funding Information:
Acknowledgement This work was supported in part by New Energy and Industrial Technology Development Organization (NEDO) in Japan.
PY - 2009/11
Y1 - 2009/11
N2 - N-Acetylglucosamine 6-O-sulfotransferase-2 (GlcNAc6ST2) is ectopically expressed in ovarian mucinous and clear cell adenocarcinoma [Kanoh et al., Glycoconj J 23:453-460, 2006]. Here we studied whether GlcNAc6ST2 protein can be detected in sera from patients with gynecological cancers and could serve as a tumor marker. First, we created a monoclonal antibody and polyclonal antiserum against GlcNAc6ST2. These antibodies were specific for GlcNAc6ST2, as shown by Western blot analysis and immunoprecipitation. Using these antibodies, we constructed a sandwich ELISA method for detecting GlcNAc6ST2 in the serum. GlcNAc6ST2 provided lower positive rates for ovarian cancer than CA125, but higher positive rates for uterine cervical and corpus cancer than SCC antigens and CA125, respectively. A significantly higher percentage of stage I uterine cervical and corpus cancers were positive for GlcNAc6ST2 than for SCC antigens and CA125, respectively. GlcNAc6ST2 could therefore be a good serological marker for detecting early-stage uterine cervical and corpus cancers.
AB - N-Acetylglucosamine 6-O-sulfotransferase-2 (GlcNAc6ST2) is ectopically expressed in ovarian mucinous and clear cell adenocarcinoma [Kanoh et al., Glycoconj J 23:453-460, 2006]. Here we studied whether GlcNAc6ST2 protein can be detected in sera from patients with gynecological cancers and could serve as a tumor marker. First, we created a monoclonal antibody and polyclonal antiserum against GlcNAc6ST2. These antibodies were specific for GlcNAc6ST2, as shown by Western blot analysis and immunoprecipitation. Using these antibodies, we constructed a sandwich ELISA method for detecting GlcNAc6ST2 in the serum. GlcNAc6ST2 provided lower positive rates for ovarian cancer than CA125, but higher positive rates for uterine cervical and corpus cancer than SCC antigens and CA125, respectively. A significantly higher percentage of stage I uterine cervical and corpus cancers were positive for GlcNAc6ST2 than for SCC antigens and CA125, respectively. GlcNAc6ST2 could therefore be a good serological marker for detecting early-stage uterine cervical and corpus cancers.
KW - Ovarian cancer
KW - Sandwich ELISA
KW - Sulfotransferase
KW - Tumor marker
KW - Uterine cervical cancer
KW - Uterine corpus cancer
UR - http://www.scopus.com/inward/record.url?scp=72649087617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72649087617&partnerID=8YFLogxK
U2 - 10.1007/s10719-008-9227-4
DO - 10.1007/s10719-008-9227-4
M3 - Article
C2 - 19156517
AN - SCOPUS:72649087617
VL - 26
SP - 1065
EP - 1073
JO - Glycoconjugate Journal
JF - Glycoconjugate Journal
SN - 0282-0080
IS - 8
ER -
